{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:15:52Z","timestamp":1787242552696,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd009734.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T00:00:00Z","timestamp":1515369600000}}],"reference-count":54,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009734.pub3","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T00:11:22Z","timestamp":1515370282000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity"],"prefix":"10.1002","volume":"2018","author":[{"given":"Mari Jeeva","family":"Sankar","sequence":"first","affiliation":[{"name":"All India Institute of Medical Sciences; Newborn Health Knowledge Centre, WHO Collaborating Centre for Training and Research in Newborn Care, Department of Pediatrics; Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhuma","family":"Sankar","sequence":"additional","affiliation":[{"name":"All India Institute of Medical Sciences; Department of Pediatrics; New Delhi New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parijat","family":"Chandra","sequence":"additional","affiliation":[{"name":"Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences (AIIMS); New Delhi Delhi India 110029"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,8]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD009734.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5301\/ejo.5000166","article-title":"Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II","volume":"22","author":"Autrata","year":"2012","journal-title":"European Journal of Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD009734.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD009734.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0004|cit4","unstructured":"NCT00622726 Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT-ROP) clinicaltrials.gov\/ct2\/show\/NCT00622726"},{"issue":"6","key":"10.1002\/14651858.CD009734.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1111\/aos.13008","article-title":"Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity","volume":"94","author":"Karkhaneh","year":"2016","journal-title":"Acta Ophthalmologica"},{"issue":"11","key":"10.1002\/14651858.CD009734.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009734.pub3-BIB0007|cit7","first-page":"355","article-title":"Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up","volume":"109","author":"O'Keeffe","year":"2016","journal-title":"Irish Medical Journal"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0008|cit8","unstructured":"Zhang G Yang M Zeng J Vakros G Su K Chen M Shenzhen Screening for Retinopathy of Prematurity Cooperative Group Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity Retina 10.1097\/IAE.0000000000001241"},{"issue":"3","key":"10.1002\/14651858.CD009734.pub3-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000449530","article-title":"The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab","volume":"236","author":"Alyamac Sukgen","year":"2016","journal-title":"Ophthalmologica. Journal International d'Ophtalmologie [International Journal of Ophthalmology]"},{"issue":"6","key":"10.1002\/14651858.CD009734.pub3-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3109\/02713683.2014.941070","article-title":"Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"40","author":"Araz-Ersan","year":"2015","journal-title":"Current Eye Research"},{"issue":"4","key":"10.1002\/14651858.CD009734.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina (Philadelphia, Pa.)"},{"issue":"6","key":"10.1002\/14651858.CD009734.pub3-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5935\/0004-2749.20150090","article-title":"Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity","volume":"78","author":"Erol","year":"2015","journal-title":"Arquivos Brasileiros de Oftalmologia"},{"issue":"3","key":"10.1002\/14651858.CD009734.pub3-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey","volume":"42","author":"Gunay","year":"2016","journal-title":"Current Eye Research"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0014|cit14","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13004","article-title":"Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison","author":"Han","journal-title":"Acta Ophthalmologica"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0015|cit15","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2016.1264607","article-title":"Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children","author":"Kabatas","journal-title":"Current Eye Research"},{"issue":"1","key":"10.1002\/14651858.CD009734.pub3-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2147\/OPTH.S110717","article-title":"Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity","volume":"10","author":"Lin","year":"2016","journal-title":"Clinical Ophthalmology (Auckland, NZ)"},{"issue":"4","key":"10.1002\/14651858.CD009734.pub3-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD009734.pub3-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina (Philadelphia, Pa.)"},{"issue":"1","key":"10.1002\/14651858.CD009734.pub3-BIB0020|cit20","first-page":"29","article-title":"Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II - four years results","volume":"68","author":"Autrata","year":"2012","journal-title":"Ceska a Slovenska Oftalmologie"},{"issue":"2","key":"10.1002\/14651858.CD009734.pub3-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Moran S O'Keefe M Hartnett C Lanigan B Murphy J Donoghue V Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity Acta Ophthalmologica 2014 e496 7 10.1111\/aos.12339","DOI":"10.1111\/aos.12339"},{"issue":"23","key":"10.1002\/14651858.CD009734.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","article-title":"Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins","volume":"92","author":"Aiello","year":"1995","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1002\/14651858.CD009734.pub3-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1542\/peds.2005-2749","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"117","author":"Section on Ophthalmology American Academy of","year":"2006","journal-title":"Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD009734.pub3-BIB0025|cit25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001693","article-title":"Peripheral retinal ablation for threshold retinopathy of prematurity in preterm infants","author":"Andersen","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD009734.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/bjo.37.9.513","article-title":"Role of oxygen in the genesis of retrolental fibroplasia; a preliminary report","volume":"37","author":"Ashton","year":"1953","journal-title":"British Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD009734.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/bjo.38.7.397","article-title":"Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia","volume":"38","author":"Ashton","year":"1954","journal-title":"British Journal of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD009734.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archopht.1984.01040030908011","article-title":"An international classification of retinopathy of prematurity","volume":"102","author":"The Committee for the Classification of Retinopathy of Prematurity","year":"1984","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0029|cit29","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"12","key":"10.1002\/14651858.CD009734.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy Of Prematurity randomized trial","volume":"121","author":"Early Treatment for Retinopathy Of Prematurity Cooperative Group","year":"2003","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD009734.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1542\/peds.2004-1180","article-title":"Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs","volume":"115","author":"Gilbert","year":"2005","journal-title":"Pediatrics"},{"issue":"67","key":"10.1002\/14651858.CD009734.pub3-BIB0032|cit32","first-page":"46","article-title":"Twenty years of childhood blindness: what have we learnt?","volume":"21","author":"Gilbert","year":"2008","journal-title":"Community Eye Health\/International Centre for Eye Health"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0033|cit33","unstructured":"McMaster University (developed by Evidence Prime). Available at gradepro.org GRADEpro GDT 2015"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0035|cit35","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0036|cit36","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"8","key":"10.1002\/14651858.CD009734.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archophthalmol.2008.1","article-title":"Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study","volume":"126","author":"Kong","year":"2008","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009734.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0002-9440(10)65004-3","article-title":"Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity","volume":"156","author":"Lashkari","year":"2000","journal-title":"American Journal of Pathology"},{"issue":"1","key":"10.1002\/14651858.CD009734.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaapos.2009.10.011","article-title":"Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"14","author":"Law","year":"2010","journal-title":"Journal of AAPOS"},{"issue":"2","key":"10.1002\/14651858.CD009734.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/08820530902800322","article-title":"Emerging treatments for retinopathy of prematurity","volume":"24","author":"Mantagos","year":"2009","journal-title":"Seminars in Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009734.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ajo.2009.05.031","article-title":"A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity","volume":"148","author":"Micieli","year":"2009","journal-title":"American Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD009734.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II","volume":"28","author":"Mintz-Hittner","year":"2008","journal-title":"Retina"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.12659\/MSM.897095","article-title":"Regression rates following the treatment of aggressive posterior retinopathy of prematurity with bevacizumab versus laser: 8-year retrospective analysis","volume":"22","author":"Nicoar\u0103","year":"2016","journal-title":"Medical Science Monitor"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0044|cit44","unstructured":"Palmer EA What have we learned about retinopathy of prematurity during the past ten years? Progress in retinopathy of prematurity. The International Symposium on Retinopathy of Prematurity; 1997; Taormina, Italy Amsterdam\/New York Kugler Publications 1997"},{"issue":"6","key":"10.1002\/14651858.CD009734.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","article-title":"A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity","volume":"10","author":"Pertl","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0046|cit46","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0047|cit47","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A (editors) Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"issue":"1","key":"10.1002\/14651858.CD009734.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0301-4738.29505","article-title":"Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity","volume":"55","author":"Shah","year":"2007","journal-title":"Indian Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD009734.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1084-2756(03)00119-2","article-title":"Pathogenesis of retinopathy of prematurity","volume":"8","author":"Smith","year":"2003","journal-title":"Seminars in Neonatology"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0050|cit50","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD009734.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ajo.2005.07.034","article-title":"Retinopathy of prematurity: the life of a lifetime disease","volume":"141","author":"Tasman","year":"2006","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD009734.pub3-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Ueta T Yanagi Y Tamaki Y Yamaguchi T Cerebrovascular accidents in ranibizumab Ophthalmology 2009 362","DOI":"10.1016\/j.ophtha.2008.09.046"},{"issue":"1","key":"10.1002\/14651858.CD009734.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","article-title":"An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan","volume":"155","author":"Wu","year":"2013","journal-title":"American Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009734.pub3-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","author":"Sankar","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009734.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T12:04:16Z","timestamp":1703073856000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009734.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Neonatal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,1,8]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009734.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,8]]}}}